Canadian and Hong Kong Patents Continue to Strengthen Intellectual Property Protection Across Envoy Medical's Fully Implanted Hearing Platform
White Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international patents, expanding its global intellectual property portfolio to 97 patents, consisting of 40 U.S. and 57 foreign patents. In addition, the Company has 26 pending foreign applications and 9 pending U.S. applications.
"As a company known for fully implanted hearing devices that leverage the natural ear to pick up sound rather than requiring an external or sub-dermal microphone, Envoy Medical has successfully differentiated itself from other companies. We will continue to invest in intellectual property protection domestically and internationally as we add to our portfolio and further separate ourselves from what others are doing," said Brent Lucas, Chief Executive Officer of Envoy Medical. "While each patent has its place, the sum of our overall strategy is much more valuable than the individual parts. Combining our intellectual property with the courage to put forward different architectures is what will ultimately set us apart for years to come."
The Canadian Patent Office granted Canadian Patent No. 3,130,978 to Envoy Medical, titled "Implantable Cochlear System with Integrated Components and Lead Characterization." The patent covers technology related to characterizing electrical conductors within an implantable cochlear system and supports the Company's strategy for future developments in integrated implantable hearing technology.
The Hong Kong Patent Office granted Hong Kong Patent No. HK40108431 to Envoy Medical, titled "Implantable Cochlear System and Corresponding Method of Compensating for Variability in a Middle Ear Sensor." The patent covers systems and methods designed to compensate for variability in a middle ear sensor, including techniques for processing and normalizing signals received from the sensor. This patent helps protect Envoy Medical's approach of using technology that works with the ear to pick up sound, rather than a microphone.
Expanding Global Intellectual Property Portfolio
Envoy Medical's intellectual property portfolio spans technologies and ideas supporting current developments as well as future improvements of its fully implanted hearing platform or technology, including sensing, signal processing, implantation and system integration.
Envoy Medical's global patent portfolio now consists of:
The foreign patent count includes, for granted European cases, the European Patent ("EP") separately from and in addition to corresponding individual country validations and unitary patents.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the investigational fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim CI received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
The Acclaim CI is currently under investigation as part of a U.S.-based pivotal clinical trial. For more information on the trial, visit www.envoymedical.com/acclaim-pivotal.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.